Monosomy 3 by chromogenic in situ hybridization (CISH) in Iranian patients with uveal melanoma  by Naseripour, Masood et al.
Available online at www.sciencedirect.comhttp://dx.doi.org/
2452-2325/& 20
(http://creativeco
nCorrespondin
Sciences (IUMS
Tehran, Iran.
E-mail addre
Peer review uJournal of Current Ophthalmology 27 (2015) 41–45
http://www.journals.elsevier.com/journal-of-current-ophthalmologyMonosomy 3 by chromogenic in situ hybridization (CISH) in Iranian
patients with uveal melanoma
Masood Naseripoura, Mitra Mehrazmab, Rama Pourmatina, Mohsen Bahmani Kashkoulia,
Ahad Sedaghata,n, Elmira Gheytanchib
aEye Research Center, Rassoul Akram Hospital, Ophthalmology Department, Iran University of Medical Sciences [IUMS], Tehran, Iran
bOncopathology Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences [IUMS], Tehran, Iran
Available online 4 November 2015Abstract
Purpose: The aim of this study was to investigate the rate of monosomy 3 by CISH technique in Iranian patients with uveal melanoma (UM) and
its correlation with clinical and histopathological features.
Method: Archival formalin ﬁxed, parafﬁn-embedded material from 50 patients who had undergone enucleation for large uveal melanomas was
obtained. Monosomy of chromosome 3 alteration by chromogenic in situ hybridization (CISH) was investigated. Clinical and histopathological
features of tumors were collected.
Results: The patients had a mean age of 56.677.6 years. Mean basal diameter and thickness of tumors were 14.1 mm and 10.2 mm,
respectively. Four patients (8%) were identiﬁed to harbor monosomy of chromosome 3. In the mean follow-up of 5.3 years (range, 3.2–9.5 y),
only one case with monosomy 3 died of UM metastasis. The most common type of cellularity was mixed cell (86%).
There was not any statistically signiﬁcant correlation between monosomy of chromosome 3 and type of cellularity, ciliary body involvement,
and largest basal diameter.
Conclusion: The low rate of monosomy chromosome 3 and the consequent low rate of mortality may be indicative of good prognosis in Iranian
patients with uveal melanoma.
& 2015 Iranian Society of Opthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The most common primary intraocular tumor, uveal mela-
noma (UM), has a propensity for hematogenous metastasis that
can result in death.1
Since the noteworthy report of Prescher et al2 in 1996,
several publications2–7 investigating the association between
the chromosomal abnormalities and UM survival have
revealed that the monosomy chromosome 3 is the most10.1016/j.joco.2015.09.002
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nder responsibility of the Iranian Society of Ophthalmology.frequent karyotypic abnormality in this malignant intraocular
tumor, predicting the worse prognosis. Based on the presence
or absence of this chromosomal abnormality, two distinct types
of tumors have been suggested for this entity: low grade
(class I) and high grade (class II) UM.2–8
A recent article9 on molecular classiﬁcation of UM accord-
ing to transcriptomic and chromosomal features divided the
uveal melanomas into four subgroups based on gene–
expression proﬁle and status of chromosomes 3, 6p, and 8p
to precisely predict metastatic death: class 1A with minimal
aneuploidy, class 1B with 6p gain, class 2A with monosomy 3,
and class 2B with monosomy 3 and 8p loss.
Several reports on survival analyses of UM have indicated
that monosomy 3 is a strong metastatic risk factor which can
lead to decreasing the 5-year survival from 100% to less thanlsevier B.V. This is an open access article under the CC BY-NC-ND license
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might be the early event that can lead to subsequent increased
genomic instability and a higher chance of metastasis due to
greater numbers of chromosomal abnormalities (aneuploidy) in
tumors with this abnormality.
A variety of DNA-based chromosome testing have been
used to detect monosomy 3 in UM.11
Between available techniques, chromogenic in situ hybridi-
zation (CISH) is promising as a practical, cost-effective, and
valid alternative12 to ﬂuorescent in situ hybridization (FISH).
Interpretation of CISH results is not only easy, but its signals
do not generally fade over time.
The goal of this study is to investigate the cytogenetic
alteration for monosomy of chromosome 3 by CISH technique
and its correlation with clinical and histopathological prog-
nostic factors in Iranian patients with UM.
Materials and methods
Patients and tumor samples
Archival formalin ﬁxed, parafﬁn-embedded material from
50 patients who had undergone enucleation for large ciliary
body or choroidal melanoma at a referral center in Tehran, Iran
from June 2002 to June 2012 was obtained. Patients with
history of radiation, thermotherapy, and resection prior to
enucleation were excluded. The study was approved by the
Institutional Review Board of Iran University of Medical
Sciences.
Clinical and histopathologic data as well as demographic
features of each patient were collected from the charts. The
largest basal tumor diameter and tumor thickness were
measured by B-scan echography.
Follow-up data from the time of diagnosis to the end of the
study in June 2012 were completed by reviewing each patient's
charts and/or recalling the patients for comprehensive eye
examination and systemic evaluation.
Tissue section preparation
Microtome sections 3–5 mm thick were prepared on coated
glass slide super frost plus ground edges 72–90 pcs (Thermo
scientiﬁc) and incubated at 50–60 1C for 2–16 h and at 70 1C
on a hot plate. The tissue sections were dewaxed in very pure
xylene for 5 min, rehydrated in 100% ethanol for 3 min, and
washed 3 times by deionized water. Sections were bleached
using hydrogen peroxide.
Melanin bleaching method
Deparafﬁnized sections were immersed in running and dis-
tilled water and rinsed for three times in 5 min time. Subse-
quently, sections were incubated in warm dilute 3% H2O2 in
phosphate buffer (0.05 M, pH 7.4) in a staining jar heated in a
water bath at 55 1C and washed again in running water for 5 min
and in distilled water three times. Finally, sections were rinsed in
1% acetic acid solution for 2 min13 (Fig. 1).Chromogenic in situ hybridization (CISH) technique
CISH method was performed on bleached sections using the
ZytoDot CISH Implementation Kit protocol (ZytoVisions and
ZytoDot s are trademarks of ZytoVision GmbH) that is
recommended to be used with any separately available
digoxigenin-labeled ZytoDot CISH probe. The examination
was carried out in two days, including pre-treatment (dewax-
ing, proteolysis, post-ﬁxation) according to the Kit protocol. In
day one, the slides were incubated for 10 min at 70 1C
temperature, then for 5 min in xylene and 3 min in 100%
ethanol, and washed in deionized water. The slides were
transferred to the Heat Pretreatment Solution EDTA and
incubated for 15 min and then immediately placed into the
deionized water. Next, they were incubated in Pepsin Solution
for 5 min at room temperature (RT) in a humidity chamber.
Finally, the slides were dehydrated using graded alcohols in
ascending order. Hybridizations were performed using centro-
mere speciﬁc probes to chromosomes 3 (ZytoDot CEN
3 Probe, ZytoVision, Germany). The ZytoDot CEN 3 Probe
(PD25) was vortexed and pipetted 10 ml each onto individual
samples and denatured the slides at 94–95 1C for 5 min. Then
slides were incubated in a humidity chamber and hybridized
overnight at 37 1C, e.g. on a hot plate (In situ hybridization
system, Hychrome, Euroclone Company, Italy). In day two,
Wash Buffer SSC (WB1) was prepared in two staining jars,
one at RT, the other heated to 75 1C (depending on the number
of slides, the temperature should be increased by 1 1C per
slide). PBS/Tween was prepared by adding one tablet of PBS/
Tween (WB4) to 1000 ml deionized or distilled water and
dissolved. Staining jars were ﬁlled with PBS/Tween. Blocking
Solution (BS1), Mouse-Anti-DIG (AB1), Anti-Mouse-HRP-
Polymer (AB2), Mayer's Hematoxylin Solution, Mounting
Solution (alcoholic), DAB Solution, and 3% H2O2 were used
and prepared (Fig. 2).
Interpretation of results
Visualization of signals was performed using x100 objec-
tive, resulting in easily visible signals. In an interphase nucleus
of normal cells or cells without aberrations of chromosome 3,
the speciﬁc signals of hybridization of two chromosomes
3 appear as a DAB brown-colored distinct dot-shaped signal,
which can be clearly distinguished from the background
counterstained with hematoxylin. A minimum of 100 nuclei
were counted. A tumor was identiﬁed as monosomic for
chromosome 3 if the percentage of nuclei with one hybridiza-
tion site was greater than 60% of the nuclei counted. In cells
with an aneuploidy of chromosome 3, a different signal pattern
is visible in interphases.12
Retinal tissue adjacent to the tumor was used as normal
controls for comparing with the tumor cells.
Statistical analysis
Comparisons of the distributions of clinical and chromoso-
mal variables were performed with the Fisher exact test (for
Fig. 2. Chromogenic in situ hybridization (CISH). Left: melanoma hybridized with chromosome 3, showing two copies (Diasomy) in most cells. Right: melanoma
hybridized with chromosome 3, showing one copy (monosomy) in most cells (X100).
Fig. 1. Deeply pigmented Uveal Melanoma, (left) before and (right) after bleaching using diluted hydrogen peroxide for 2 h at 55 1C. H &E stain (X10).
M. Naseripour et al. / Journal of Current Ophthalmology 27 (2015) 41–45 43categorical variables) and the Mann–Whitney test (for
continuous variables).
To identify the independent value of the prognostic factors
on Disease-Free Survival (DFS), we used a multivariate Cox
proportional hazard analysis and the likelihood ratio test.
Possible prognostic factors were age at time of diagnosis, cell
type (mixed/epithelioid cell), tumor location (ciliary body/
choroid), largest tumor diameter, tumor thickness, and monos-
omy of chromosome 3. Analyses were performed using SPSS
version 18 (SPSS, Chicago, IL software), and a P value r
0.05 was considered statistically signiﬁcant.
Results
Of the 50 participants in this study, 22 (44%) were male,
and 28 (56%) were female. The mean age at the time of
diagnosis was 56.6 years (range, 42–78 years, SD = 77.6).
The mean and median of the largest basal diameter were
14.1 (SD = 71.4) and 14.5 mm (range 9–15.8), respectively.
The average thickness was 10.2 7 1.3 mm (range, 7.2–12.5).
Thirty-nine (78%) tumors were located in the choroid, and
eleven (22%) tumors showed ciliochoroidal involvement. Cell
type was classiﬁed as mixed in forty-three (86%) and
epithelioid in seven (14%) tumors. None of them was
classiﬁed as spindle cell type.
Based on the CISH analysis, genomic abnormality of
monosomy of chromosome 3 was determined in four (8%)
of the 50 specimens. Only one (2%) patient with monosomy of
chromosome 3 died of liver metastasis, and three other patients
were alive at the end of the study. The patient with livermetastasis was a 62-year-old female with mixed-type choroidal
malignant melanoma. The largest diameter of the tumor was
12.80 mm, and the thickness was 11.10 mm.
Univariate analysis of the single possible prognostic factors did
not show a statistically signiﬁcantly higher metastasis incidence
rate in patients with potential prognostic factors such as gender,
age at time of diagnosis, mixed/epithelioid cell type in the tumor,
tumor location, and monosomy of chromosome 3 tumors com-
pared with patients without this chromosomal alteration.
Cytogenetic abnormality (monosomy of chromosome 3) was
not correlated with gender, age, ciliary body involvement, basal
tumor diameter and thickness, or epithelioid cell type (Table 1).
The mean tumor basal diameter in tumors involving ciliary
body was 12.6 7 2.03 (SD), which was signiﬁcantly smaller
than the mean value in tumors involving choroid; 14.5 7 0.8
(P o 0.0001).
The mean tumor thickness in tumors involving ciliary body
was signiﬁcantly larger than in tumors involving only the
choroid, (11.0 7 1.30 mm vs. 10.0 7 1.2 mm; P = 0.019).
The mean follow-up time for all of the patients was 63.7
months (median, 64.2; range, 38.4–115.2). The mean follow-
up time for the patients with cytogenetic evidence of monos-
omy of Chromosome 3 was 45.2 months (median, 45.8; range,
16.8–51.6), and the follow-up time for the only patient who
died of metastasis of UM was 16.8 months.
Discussion
To the best of our knowledge, this is the ﬁrst study on the
incidence of monosomy of chromosome 3 in UM in Middle
Table 1
Correlation between monosomy of Ch. 3 and clinical data.
Clinical data Monosomy of Ch. 3
Pos. Neg. P*
Gender 0.598a
Male 2 20
Female 2 26
Mean age (y) 62 64 0.327b
Cell type 0.536a
Mixed 4 39
Epithelioid 0 7
Mean tumor diameter (mm) 14.2 14.1 0.956b
Mean tumor thickness (mm) 10.0 11.0 0.761b
Involvement of ciliary body 0.357a
Yes 0 35
No 4 11
aComparison among different subgroups within a chromosome aberration
group (P calculated by the Fisher exact test).
bComparison of means among different subgroups within a chromosome
aberration group, (P calculated by Mann–Whitney test).
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study failed to show any correlation between monosomy 3 and
clinical or histopathological features of tumors. Similarly,
Aalto et al14 did not ﬁnd any association between clinico-
pathologic parameters (e.g., cell type, tumor size, and location)
and chromosomal alterations.
In contrast, several other studies have shown a correlation
between monosomy 3 and more aggressive histopathologic
and clinical factors including the largest basal diameter, ciliary
body involvement, closed vascular loop, and epithelioid type
cellularity.2,5,7,15
Because of signiﬁcant variability in clinical and histopatho-
logical parameters and the presence of focal or diffuse
heterogeneity16 of monosomy 3 in UM and different techni-
ques17 employed to report this abnormality, it has been
emphasized that they should be interpreted together to enhance
prediction of disease-speciﬁc mortality in this tumor.7
Although several techniques have been introduced to detect
monosomy 3, no consensus has been reported in terms of
standard protocol and method between different centers.18
Depending on tumor features and cytogenetic techniques
used, the detection rate of monosomy 3 ranges from as low as
12% to as high as 65%.17 The role of monosomy 3 as a major
risk factor in UM has been conﬁrmed in different studies,
despite diversity in techniques. In our study, the testing of
chromosome 3 alteration by CISH technique may not have
detected all cases with monosomy 3, making it necessary to
conﬁrm the results by other sophisticated cytogenetic tests,
such as multiplex ligation-dependent probe ampliﬁcation
(MLPA), which has been suggested by Damato et al,19 or
microsatellite analysis (MSA), which has been advocated by
Thomas et al.20
As proposed by Sandinha et al,12 we reported a tumor as
monosomic for chromosome 3 if the percentage of nuclei with
one hybridization site was greater than 60% of the nuclei
counted. Therefore, the lower detection rate in our study mightbe due to a relatively high threshold of 60%, which was
considered to deﬁne monosomy 3 status by CISH technique.
The low incidence of monosomy 3 along with 2% mortality
rate in our study are in accordance with published data from
other Asian countries.21,22
Epidemiologic data on population-based incidence of UM
by Hu et al23 showed that the relative risk of UM was 1.2 for
Asian and Paciﬁc Islander patients, 5.4 for Hispanic patients,
and 19.2 for non-Hispanic white patients as compared with
black patients.
They calculated that the annual age-adjusted incidence rate of
UM per million population was 0.31 for African-Americans, 0.38
for Asians, 1.67 for Hispanics, and 6.02 for non-Hispanic
Caucasians.
The same variability have been suggested in biological
features and clinical presentation by some authors between
different ethnic groups.24–26
These facts may be indicative that the role of race as an
independent prognostic factor should also be investigated in
detail in UM.
Our study had some limitations. We included small sample
size of patients from one referral center, which is not
representative of the entire Iranian population. A multivariate
analysis of different clinical and cytogenetic prognostic factors
was impossible due to the small sample size, and additional
studies with a larger sample size to investigate the correlation
of monosomy 3 with metastasis-related death will be required.
We did not perform any other method to validate the results of
CISH technique. The lower rate of monosomy 3, might be due
to sampling error and tumor heterogeneity.
Furthermore, despite choosing the best method of bleaching
for lessening the interference with hybridization, bleaching
tissue sections in heavily pigmented specimens in our study
inevitably affected the quality of CISH sections. Interpretation
difﬁculties also were encountered with overlapping nuclei,
particulate debris on slides, and also with highly pigmented
tissues that were not completely depigmented due to signal
interference by residual pigments.
In conclusion, our results demonstrated the less frequent
events of monosomy chromosome 3, epithelioid cellularity,
and lower rate of UM-related death in Iranian patients, which
is different from previously published reports in Caucasian
populations harboring this tumor.
The value of our report is enhanced by the fact that the
incidence of this cytogenetic abnormality in Iranian patients is
the lowest rate that has been reported so far. Further studies are
warranted to evaluate the different aspects of chromosomal
abnormalities and clinical characteristics in UM as well as their
correlation among different non-Caucasian ethnic groups.
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